Friday, April 29, 2016

Traders continue to pile into the Japanese yen

Traders continue to pile into the Japanese yen

Japan liquidityJunko Kimura/Getty Images
It’s tough being a central banker in this day and age, particularly if you fail to deliver on lofty market expectations. 
Haruhiko Kuroda, governor of the Bank of Japan, is one man who likely understands this more than most today.
After stunning financial markets for the second time in three months yesterday, this time for not easing monetary policy as opposed to January when it did, the Japanese yen has soared over the past 24 hours, doing little to help spur on inflationary pressures that Kuroda and the BOJ board so desperately desire.
On Thursday the USD/JPY fell 3.02%, the largest percentage fall seen since March 16, 2011. That was when global markets were in free fall over the potential for nuclear meltdown at the crippled Fukushima nuclear plant.
Now, with Japan on holidays, the yen is continuing to surge, with the USD/JPY dropping to as low as 107.09 on Friday, a low not seen since October 2014.
Ouch. 
Here’s a chart that everyone will be talking about today, the dollar-yen.
USDJPY daily apr 29 2016Business Insider Australia
Given the reaction in the yen to the BOJ not easing policy yesterday, and that seen in the New Zealand dollar to the same stance adopted by the Reserve Bank of New Zealand just hours earlier, there’s more than a risk that a similar outcome could arrive for the Australian dollar next Tuesday should the RBA do the same.
Read the original article on Business Insider Australia. Copyright 2016. Follow Business Insider Australia on Twitter.

Europe is back in deflation

Europe is back in deflation

deflate deflationMichael Loccisano/Getty Images
The eurozone slipped back into deflation in April, according to the latest numbers released by Eurostat on Friday morning.
Eurostat's latest flash data showed that consumer prices in the single currency area fell by 0.2% in April.
Economists had expected inflation to fall by 0.1%, slipping from the 0.0% at March's reading, so the reading is troubling.
The number means that prices are once again falling, having come out of deflationary territory in March, and are well behind the 2% target set by the ECB for inflation.
On a year-to-year basis core consumer prices grew by 0.8%, against a forecast of 0.9% and a previous reading of 1%. 
Core prices are an important measure because they strip out the most volatile items — things like fuel and food prices, which are subject to massive variations. 
It is worth noting that Friday's data is just a flash reading, meaning that it could be revised when the final numbers drop in mid-May.
Here's an extract from Eurostat's release accompanying the data:
Looking at the main components of euro area inflation, services is expected to have the highest annual rate in April (1.0%, compared with 1.4% in March), followed by food, alcohol & tobacco (0.8%, stable compared with March), non-energy industrial goods, (0.5%, stable compared with March) and energy (-8.6%, compared with -8.7% in March).
A large part of the eurozone's extremely low inflation right now is down to the slump in the price of oil over the last year — but the core figure shows that other prices aren't rising by as much as the ECB would like, either. Here's a breakdown of the core areas of goods tracked by Eurostat:
Euro flash inflation aprilEurostat
The eurozone has been flirting with price deflation for the past year or so, largely hovering just above zero since early 2015, but slipping below zero a couple of times in early 2016. 
Friday's eurozone CPI figures are the third set to be released since European Central Bank and its president Mario Draghi announced a series of new monetary policy measures, including cutting all its base rates, and extending its programme of bond buying.
The measures are designed to try and boost stalling inflation, as well as growth, within the Eurozone. So far the ECB's negative interest rate policy (NIRP) hasn't managed to stimulate inflation, although Draghi said in an interview with German newspaper Bild this week that "our policy is working" when speaking about criticisms of the ECB.

Thursday, April 28, 2016

Anglo American just raised $1.5 billion selling 2 mining businesses to China

Anglo American just raised $1.5 billion selling 2 mining businesses to China

A miner smokes after his work as he leaves a coal mine from the state-owned Longmay Group on the outskirts of Jixi, in Heilongjiang province, China, October 24, 2015. To match story CHINA-COAL/JIXI Picture taken on October 24, 2015.REUTERS/Jason LeeA Chinese miner.
Mining giant Anglo American is making progress on its quest to chip away at its $12.9 billion (£8.8 billion) debt pile, raising $1.5 billion (£1 billion) to do just that by selling off two of its businesses.
Anglo announced on Thursday that it is selling its Niobium and Phosphates businesses for a total cash consideration of $1.5 billion to China Molybdenum, a state-owned mining giant. The businesses are both based in Brazil and include chemical plants and processing facilities.
Anglo, which owns De Beers diamonds, said the proceeds of the sale will go towards reducing the company's debt to below $10 billion (£6.8 billion) as part of its long-term plan set out in February. The company plans to sell between $5-6 billion (£3.4-4.1 billion) of assets and reduce its core staff from 11,500 to just 5,000.
CEO Mark Cutifani says in Thursday's statement:
The sale of our Niobium and Phosphates businesses is another positive step forward in the strategic reshaping of Anglo American that we set out in February. The proceeds from this Transaction, together with the ongoing productivity and cost improvements we are driving through the business, will enable us to continue to reduce our net debt towards our targeted level of less than $10 billion at the end of 2016. This Transaction confirms our commitment to creating the new Anglo American, positioned to deliver robust profitability and cash flows through the price cycle.
Anglo reported an annual loss of $5.4 billion (£3.7 billion) in February. Like most miners, the company is struggling with a slump in demand from China, which in turn has led to a slump in prices for raw materials.
Anglo shares are up over 4% after almost an hour's trading in London.AngloInvesting.com


Deutsche Bank's profit plunged 58% in 'challenging' markets

Deutsche Bank's profit plunged 58% in 'challenging' markets

Deutsche BankREUTERS/Luke MacGregorDeutsche Bank offices in London seen in 2013.
Net income at Deutsche Bank fell 58% in the first quarter of 2016 to €236 million (£183 million).
The bank had made €559 million in the same period (January to March) last year.
While it sounds bad, it could have been about half a billion euros worse – analysts expected a loss of €249 million, according to a Reuters poll.
John Cryan, co-CEO of Deutsche Bank, said: “Financial markets were challenging during the first quarter, largely reflecting concerns about the outlook for the global economy."
"This uncertainty led to a decline in client activity in the capital markets, and our revenues fell from the prior year, most notably in our trading and corporate finance businesses. Our results reflect these challenging conditions as well as the impact of our strategic decisions to exit or reduce significantly selected businesses,” Cryan said in a statement on Thursday.
The drag on revenue and profit came mostly from the investment banking and markets division. Debt sales and trading revenues were €2 billion euros, down 29% year-on-year. Equity sales and trading revenues saw the same 29% drop to €728 million.
Deutsche Bank has had a volatile year.
The bank announced a new lineup at the top of the markets business in November. Ram Nayak was appointed to lead a new debt-trading unit that combined rates, credit, foreign exchange, emerging-market debt, and structured-finance trading. Sam Wisnia heads rates in Europe and the Americas.
It then found itself the subject of speculation in February as investors fretted over its ability to pay the coupon on contingent bonds, and credit default swaps on the bank's debt widened dramatically.
Shares were up on the news in early trading on Thursday:
DB1Investing

Bill Ackman and Valeant execs just got through one of the most brutal Senate hearings we've ever seen

Bill Ackman and Valeant execs just got through one of the most brutal Senate hearings we've ever seen

Valeant Pharmaceuticals' outgoing CEO, Mike Pearson, the company's former interim CEO, Howard Schiller, and board member and hedge fund billionaire Bill Ackman all just testified before the US Senate.
They were answering questions about the company's practice of buying drugs and jacking up their prices.
Not surprisingly, they walked into a very aggressive room.
Ranking member Claire McCaskill(D-Missouri) of the Senate Special Committee on Aging was direct from the start. In her opening statement she said:
In case you haven't noticed, that has real ramifications in our political process and could lead to an instability of our government, our economy, and our standing in the world. Pigs get fed, hogs get slaughtered. It's time to slaughter some hogs. I thank the witnesses for being here today, and I look forward to hearing their testimony.
Here are the highlights:
  • Pearson was questioned about Valeant's R&D spending, its patient-assistance program, and its drug-pricing policy.
  • He was also asked about a Wells Fargo note that said Valeant had raised prices on 16 of its products in the past year.
  • Bill Ackman said that he was focused on saving Valeant from bankruptcy.
  • He was also questioned about his investments in Herbalife and Fannie and Freddie.
  • "Can you find me one drug that Valeant didn't raise the price on?" McCaskill asked.
  • Neither Ackman nor Pearson could find one.
Here's how it went down:

Pearson

"I've got a list of 20 drugs that you guys have raised over 200% in a matter of years," said McCaskill.
She had gotten that list from the US House of Representatives, which is also investigating Valeant for the same issue. She considers that matter an issue of national debt because healthcare costs drive the debt so high.
"I don't think you guys understand that you can't do this just because" it's legal, she said.
McCaskill pointed out that Valeant's top 30 drugs increased in price by 70% from this time last year.
"It couldn't have been because of R&D because you don't spend that much," she said.
"We have not raised prices at all this year in terms of the neurology and other products," Pearson said. He also said that it reduced prices for dermatology drugs.
This runs counter to a report from Wells Fargo released on Wednesday morning that showed that the company raised prices for 16 drugs. Pearson said that the report was likely inaccurate, though he hadn't seen it.
Pearson also went back to discussing how much Valeant spends on patient-assistance programs — programs that people in a previous panel said didn't really help anyone. The committee members didn't let him get away with that either, pointing out that these programs allow Valeant to maintain price and that Valeant has a "captive audience."
Sen. Joe Donnelly (D-Indiana) pointed out that even the largest Catholic hospital system in the world couldn't use Valeant's "volume based" assistance program.
"It's a human right not to be treated this way," said Donnelly.
Another senator called Valeant's response to a patient on why it increased the price of a Wilson-disease drug "a red herring."
Valeant responded to the patient with a letter saying that "the investment to develop and distribute novel medicines" would not be worth it unless the company could increase prices for a bigger return on investment.
This letter came up over and over in the hearing.
Valeant bought the drug, the senator pointed out, and spent no money developing it.
He later asked, "Did you just now realize" that this was a life-and-death situation for some patients?
Pearson said that he did not.
Mike Pearson senateScreenshot/ABC News

Ackman

Hedge fund billionaire Bill Ackman, who has been a big Valeant shareholder for over a year, opened with this gem: "As a shareholder of Valeant, I recognize my investment was an ... endorsement of Valeant's strategy."
Then he went on to talk about the changes he's trying to make to the company since he got on the board and admitted that price increases broke a "social contract" with Valeant's customers.
There was a lot of stuff that was in Ackman's written testimony that wasn't actually said. Like this:
We believe that a drug company can do as much or more for innovation in pharma by acquiring other drug companies and licensing drugs than by developing drugs internally. Much of Valeant's product portfolio has been built through acquisition where Valeant was the high bidder for smaller innovative companies and their products. As a result of these acquisitions, the selling company shareholders earned an attractive and in some cases spectacular return on their investment from the nearly $40 billion that Valeant has invested in acquisitions. We expect that a high percentage of the after-tax capital received by these selling shareholders is likely to have already been reinvested in other early-stage and innovative drug companies so the cycle of drug development can continue.
You can imagine why that would not have gone over well. After one line of questioning, Ackman said that he texted Valeant's board chairman to schedule a call tomorrow to discuss lowering prices for two heart drugs.
Bill Ackman senateScreenshot/ABC News
McCaskill nailed Ackman for not knowing about Valeant's price increases, naming drugs and hikes and a letter a patient sent to Ackman.
"Yeah, it's horrible. It's wrong," he said.
"One of the things with due diligence in this industry is that it's really hard to find out prices for drugs," Ackman said after stuttering a bit.
We should note that some of these price increases are documented by researcher IMG.
"Can you find me one drug that Valeant didn't raise the price on?" McCaskill asked.
Neither Ackman nor Pearson could find one.
Another senator asked Ackman if he thought that his public and private pension investors want him to invest in this kind of business model.
"Certainly not," he responded.
Then he went on to say that what attracted him to the company were its segments, like consumer brands, that weren't overpriced.
Of course, there had to be an attack on hedge funds, too.
"It's shocking the way hedge funds try to change public policy in order to benefit them," said Sen. Bob Corker (R-Tennessee).
He pointed to a potential Puerto Rico bailout as a policy hedge funds are trying to shape. He also brought up Ackman's aggressive attack against Herbalife, his famous short.
He asked where else Ackman has tried to shape public policy.
"Herbalife is the only one ... I can think of," Ackman said.
"Really?" Corker asked, bringing up Fannie Mae and Freddie Mac. Then they talked about Fannie and Freddie as if the rest of us weren't even there to talk about Valeant.
Sen. Bob Casey (D-Pennsylvania) pointed out that Ackman said that drug pricing was a "serious issue."
Casey continued: "Can you point to anything in your testimony here that points to social responsibility?"
Ackman went back to his written testimony, which lacked the specifics Casey wanted.
"The first thing I've been doing is trying to make sure this company doesn't go bankrupt," said Ackman, adding that the company expected to file its annual report by Friday and was replacing the CEO.
Casey was still not satisfied. "I've heard of no policy ... in regards to pricing that says, 'It shall be the policy of this company to not do this.'"
Ackman said that he would "have that in weeks. Watch what we can do."

Elizabeth Warren

Sen. Elizabeth Warren (D-Massachusetts) is not a fan of Wall Street's financial engineering. So, shocking no one, she came in aggressive.
"You double the price [of a drug] even if you get a waiver to the customer, you make a lot of money," Warren said.
She pointed out that the drug industry spent $7 billion on patient-assistance programs in order to maintain high prices and line their pockets.
"What is the return on investment to Valeant on the money you're currently putting into the patient-assistance programs?" she asked.
Pearson said that he didn't know.
"Don't tell me you've never done the analysis ... By doing this you ... keep the patient on the more expensive drug and then you ... recoup whatever from the insurance company. What I'm saying is that this must be a profitable ... for you ... You're making more money ... You haven't done that analysis?" she said.
Pearson said no.
Warren asked why these programs can't be used on government insurance and answered her own question: It's illegal. She said that government agencies know that the patient-assistance programs are just a way for drug companies to maintain price, and demanded immediate action.

Schiller

Valeant's former interim CEO and CFO, Howard Schiller, kept his opening statement light. He has already been in the hot seat since he filled in for Pearson at a hearing earlier this year. He was barely asked any questions during that hearing.

Facebook crushes expectations, stock soars

Facebook crushes expectations, stock soars

Facebook reported its Q1 earningson Wednesday afternoon, beating expectations on the top and bottom lines.
The stock surged nearly 9% after-hours.
Here are the most important numbers:
  • Earnings per share:$0.77 vs. $0.62 expected.
  • Revenue: $5.38 billion vs. $5.25 billion expected, and up 52% year-over-year. Ad revenue is up 57% year-over-year.
  • Monthly active users:1.65 billion vs. 1.62 billion expected.
  • Daily active users: 1.09 billion on average forMarch 2016. This quarter, 66% of Facebook's monthly active users (MAU) were daily active users, which is up from 65% during the same period last year.
Along with strong growth across the board on those key numbers, Facebook also once again proved that its mobile business is thriving. It had 1.51 billionmobile MAUs, up 21% year-over-year, and the company made 82% of its advertising revenue from mobile this quarter, versus 73% at this time last year.
There are 894 million monthly active users who check only Facebook on their smartphones. On the company's earnings call, CEO Mark Zuckerberg said that people spend on average more than 50 minutes a day across its suite of apps, excluding WhatsApp. In regards to WhatsApp, he also said that it plans to focus on "growth and engagement" instead of diving into sponsored posts like Messenger has.
Outside of ad revenues, Facebook makes a small amount of money from payments and other fees: $181 million this quarter, which is down 20% year-over-year — the company has previously attributed this decline to a drop in revenue from gaming apps.
The company is also proposing a new class of nonvoting stock to make sure that Zuckerberg retains majority control:
If the proposal is approved, we intend to issue two shares of Class C capital stock as a one-time stock dividend in respect of each outstanding share of our Class A and Class B common stock. This proposal is designed to create a capital structure that will, among other things, allow us to remain focused on Mr. Zuckerberg's long-term vision for our company and encourage Mr. Zuckerberg to remain in an active leadership role at Facebook.
Here are the other important numbers:
  • Total costs and expenses were $3.37 billion, up 29% year-over-year, and capital expenditures were $1.13 billion.
  • Free cash flow for the first quarter of 2016 was $1.85 billion.
  • Facebook has 13,600 employees, up 35% from the same time last year.
  • Most of Facebook's revenue comes from North America and Europe with about only 24% ($1.3 billion) coming from Asia-Pacific and the rest of the world. But those areas account for 66% of its monthly active users. The average revenue per user in those regions is still tiny, compared to in the US: $1.56 and $0.91, respectively, versus $12.43 and $3.98 in the US and Europe.
Here's a look at where Facebook's revenue comes from geographically:
FB chartFacebook
Facebook's blockbuster earnings follow a week of disappointing results from the likes of Google, Apple, and Microsoft.
Here are the highlights from the company's call:
Zuckerberg started out by discussing the company's proposed new stock structure. He recalled how having founder control protected Facebook from selling in the early days and allowed it to buy Instagram. With the new structure, he'll be able to keep all of his power while still giving away $1 billion in shares per year.
Video was also a hot topic on the call. Facebook COO Sheryl Sandberg said that people are sharing and creating three times as much more video on the social network year-over-year, and that they're watching 40% more on Instagram in the last six months.
More generally, we also learned that Facebook's average price per ad increased 5% and impressions increased 50%.
Although the company has started rolling out ads on Messenger, it doesn't plan on doing the same for its other chat app, WhatsApp, just yet.

728 X 90

336 x 280

300 X 250

320 X 100

300 X600